Abstract
BackgroundThe novel LABA olodaterol has 24-h bronchodilator activity.ObjectiveTo evaluate the symptomatic benefit of olodaterol QD in patients with GOLD 2–4 COPD.MethodsIn replicate, randomised, double-blind, placebo-controlled, parallel-group studies, patients with post-bronchodilator...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have